• Journal Article

Who Said It Better? A Test of Wording Differences in the MedWatch "Toll-Free Statement" for Consumer Reporting of Side Effects in Direct-to-Consumer Television Advertisements

Citation

Aikin, K. J., O'Donoghue, A. C., Sullivan, H. W., Betts, K. R., & Squire, C. (2016). Who Said It Better? A Test of Wording Differences in the MedWatch "Toll-Free Statement" for Consumer Reporting of Side Effects in Direct-to-Consumer Television Advertisements. Therapeutic Innovation & Regulatory Science, 50(2), 169-173. DOI: 10.1177/2168479015596023

Abstract

Results: The FDAAA statement was more noticeable, clear, and more participants were able to recall and recognize its correct purpose. Comprehension of product risk and benefit information did not differ based on statement wording. Conclusions: Findings suggest that the FDAAA toll-free statement wording is superior to that of the TFNR.